The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Orthocell Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.385
America/New_York / 2 mai 2024 @ 22:45
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 80.59 mill |
| EPS: | -0.0400 |
| P/E: | -9.62 |
| Earnings Date: | Feb 22, 2024 |
| SharesOutstanding: | 209.33 mill |
| Avg Daily Volume: | 0.130 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -9.62 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.25x |
| Company: PE -9.62 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.370 - 0.400 ( +/- 3.90%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.385 (0.00% ) |
| Volume | 0.0662 mill |
| Avg. Vol. | 0.130 mill |
| % of Avg. Vol | 50.96 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OCC.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OCC.AX
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.